🔗 Share this article

An everyday slimming tablet may help individuals reduce their weight by as much as 20%, according to a trial that could pave the way for millions additional individuals to shed pounds.

How the Medication Functions

The drug, called the oral treatment, focuses on the same gut hormone receptors as slimming injections such as Mounjaro and semaglutide. In a trial of 3,127 adults, one in five users who used the once-a-day pill for more than a year shed 20% or more of their body weight.

Slimming injections are revolutionary, but oral forms represent a major breakthrough since they are easier to store, share and administer, and may also be projected to be more affordable, offering fresh hope for millions attempting to reduce weight.

Orforglipron is a GLP-1 agonist, a class of drug that aids in lowering glucose levels, delays the breakdown of food and may curb hunger.

Study Results and Accessibility

Slimming results seen among participants using the tablet is not as stark as those among users using injectable alternatives, but experts believe the tablet will be easier to obtain and convenient compared with injections.

The drug has not been authorized by the FDA or health authorities in other countries. The manufacturer stated it expects significant interest when the new pill is released.

During the trial, the over three thousand participants were split into groups receiving orforglipron pills of different strengths, while some received a placebo, for 72 weeks.

Each of the volunteers were diagnosed with excess weight, meaning they had a body mass index reading of 30 or over, but they were free from high blood sugar. Patients from several nations were involved in the research.

Significant Outcomes

Scientists found that after 72 weeks people on the lowest dose lost an average of 7.5% of their weight. Participants taking the maximum amount lost an mean of over 11% of their body weight.

In users using the strongest tablets, more than half had a reduction of 10% or more of weight, 36% had a loss of 15% or greater, and 18.4% had a reduction of 20% or higher.

Researchers reported additional health metrics additionally got better in people using the drug, including better BP, a smaller waist circumference and a decrease in LDL levels.

The most common side-effects were gastrointestinal, which were described as mild to moderate.

“Among participants with obesity, 72-week treatment using the medication resulted in notable reductions in weight than placebo,” the authors wrote.

Future Benefits

Medical experts have praised slimming treatments as game-changing. But injections involve extra work for health services, so oral options might help many additional people aiming to slim down.

Additional research indicates slimming injections may be successful on minors starting from six who have obesity or have type 2 diabetes. But, stomach problems were “significantly more common” in young users taking the drugs.

They said that longer observation periods in future studies and more real-world research were crucial to establish the lasting impacts.”